OrbusNeich said today it launched a Chinese trial of its Combo dual-therapy coronary stent designed to repair vessel injury and regenerate endothelium. The 436-patient randomized, non-inferiority trial has enrolled its 1st patient, the Hong Kong-based company said, and will compare the Combo stent’s effectiveness against Lepu Medical‘s Nano stent for up to 5 years. “We […]
OrbusNeich Medical said today that it enrolled the 1st U.S. patient in a pivotal trial of its dual-therapy Combo stent.
April 25, 2014 by Brian Johnson
OrbusNeich Medical said it launched a clinical trial in the U.S. and Japan for its Combo dual-therapy coronary stent as it gears up to apply for Shonin approval in Japan.
OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.